预约演示
更新于：2026-04-07
Perflutren lipid microsphere
全氟丙烷脂质微球
更新于：2026-04-07
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3F8 |
InChIKeyQYSGYZVSCZSLHT-UHFFFAOYSA-N |
CAS号76-19-7 |
关联
85
项与 全氟丙烷脂质微球 相关的临床试验NCT07501650
Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06024772
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)
NCT07436364
Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy
100 项与 全氟丙烷脂质微球 相关的临床结果
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的转化医学
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的专利（医药）
登录后查看更多信息
1,636
项与 全氟丙烷脂质微球 相关的文献（医药）2026-02-01DOCUMENTA OPHTHALMOLOGICA
Rhegmatogenous retinal detachment in gyrate atrophy: a case report and review of literature
Review
作者: Lee, Yong Min ; Agrawal, Surbhi ; Fong, Noel ; Durkin, Shane ; Franzco
PURPOSE:
We present a rare case of a 25-year-old Polish male diagnosed with rhegmatogenous retinal detachment (RRD) on a background of gyrate atrophy (GA), successfully treated with pars plana vitrectomy (PPV) combined with cryotherapy and perfluoropropane (C3F8) gas tamponade.
METHODS:
Regular ophthalmic examinations with optical coherence tomography were performed preoperatively and three months postoperatively.
RESULTS:
The patient initially presented with acute loss of vision to counting fingers in the left eye secondary to a macula-off RRD. Intraoperatively, multiple circumferential skirts of vitreous bands and a peripheral break at 11 o'clock were identified. The break was treated with cryotherapy and C3F8 gas tamponade. The patient underwent left-sided cataract surgery six months following his vitrectomy and subsequently a YAG laser posterior capsulotomy. The retina remained attached at his 9-month follow up with a final best-corrected visual acuity of 6/9-1.
CONCLUSIONS:
PPV with cryotherapy and perfluoropropane tamponade can be an effective surgical approach in the management of RRD with underlying GA. Compared to previously reported cases, a favourable visual outcome was achieved in our case, likely attributed to the absence of other ophthalmic complications (such as proliferative vitreoretinopathy) and timely surgical intervention. Recognising atypical vitreous characteristics intraoperatively may refine surgical techniques and outcomes in similar cases. Future cases could consider an encircling scleral band for additional support, particularly in cases involving inferior retinal breaks.
2025-11-01CORNEA
Carbon Footprint of Fluorinated Gases Used in Endothelial Keratoplasty
Article
作者: Gadhvi, Kunal ; Moussa, George ; Kaye, Stephen ; Raimondi, Raffaele ; Romano, Vito ; Airaldi, Matteo ; Borgia, Alfredo ; Dell’Omo, Roberto
Purpose::
The purpose of this study was to examine the direct impact on carbon emissions attributed to the use of fluorinated gases in endothelial keratoplasty (EK) procedures using gas tamponade and to evaluate the respective carbon footprint of different gas delivery systems used in EK procedures.
Methods::
In this retrospective, single-center environmental impact study, all corneal procedures using fluorinated gases between January 2021 and January 2024 at the Royal Liverpool University Hospital were reviewed and included. The CO2 equivalent emissions were calculated based on the mass of each fluorinated gas used, following the guidelines of the Intergovernmental Panel on Climate Change.
Results::
Of 357 total procedures (160 Descemet membrane endothelial keratoplasty [44.8%], 118 Descemet stripping automated endothelial keratoplasty [33.1%], and 79 rebubbling [22.1%]), single-use sulfur hexafluoride (SF6) canisters were used in 278 (77.9%) procedures. SF6 canisters used in corneal transplantation emitted nearly 1.5 tons of CO2 over 3 years. The 30-mL canisters emitted twice the CO2 per GBP compared to SF6 15-mL canisters and 4 times that of C2F6 or C3F8 15-mL canisters.
Conclusions::
Fluorinated gas use in corneal transplantation has a significant environmental impact, which can be reduced by the use of smaller single-use canisters with lower carbon footprint, although manufacturing and disposal concerns remain. Our findings advocate for a more environmentally conscious approach to EK, favoring the use of smaller, more cost-efficient canisters and considering air as an alternative tamponade where possible.
2025-11-01Archivos de la Sociedad Espanola de Oftalmologia
Analysis of factors associated with post-vitrectomy cataract formation in phakic patients undergoing vitrectomy for rhegmatogenous retinal detachment
Article
作者: Pinar-Sueiro, S ; Gibelalde, A ; Martínez-Soroa, I
INTRODUCTIONS AND OBJECTIVES:
This study assesses risk factors for developing cataracts after vitrectomy with tamponade for rhegmatogenous retinal detachment (RRD) in phakic patients and explores the potencial causal relationship between RRD surgery and the development of cataracts.
MATERIALS AND METHODS:
This was a retrospective study analysing the medical records of patients undergoing RRD surgery between 2012 and 2020 (9 years) at Donostia University Hospital (HUD). We collected data on the date of phacoemulsification surgery after vitrectomy surgery for RRD, as well as the type of vitrectomy and patient characteristics.
RESULTS:
Patients who underwent cataract surgery were on average older (mean age of 60.79 years old ± 9.49) than those who did not undergo this type of surgery during follow-up (52.97 years old ± 13.59), the difference being statistically significant (0P < .0001). Classifying patients by age at the date of the vitrectomy (≤50 years or >50 years of age), we found between-group differences in phacoemulsification rates after vitrectomy in the follow-up period, cataract surgery being performed in a third of the younger group and three-quarters of the older group (P < .0001).
CONCLUSIONS:
Patients with phakic RRD under 50 years old have a lower risk of cataract development after vitrectomy with tamponade than those over 50 years old. The use of long-acting tamponade gases such as C3F8 and silicone oil in phakic patients seems to increase the likelihood of needing early cataract surgery after RRD surgery with PPV.
100 项与 全氟丙烷脂质微球 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 中国 | 2022-11-15 | |
| 造影剂 | 美国 | 2001-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性劳累性骨筋膜室综合征 | 临床3期 | 美国 | 2020-07-01 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝细胞癌 | 临床3期 | 美国 | 2016-04-01 | |
| 心脏衰竭 | 临床2期 | 美国 | 2017-06-01 | |
| 子宫附件疾病 | 临床1期 | 美国 | 2017-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 25 | Contrast - Enhanced Ultrasound+Perflutren Lipid Microcpheres | 夢夢夢醖積鑰築繭壓簾 = 觸蓋築鑰範鏇積顧遞鏇 襯蓋夢繭膚製艱鏇齋夢 (壓蓋鹽憲齋鹹齋淵願願, 淵憲夢憲壓艱廠艱獵網 ~ 餘構簾簾餘網遞製簾遞) 更多 | - | 2026-04-02 | ||
临床2期 | 27 | Acoustic Angiography+Definity (Breast Imaging Cohort) | 製憲鹹壓襯網餘醖壓醖 = 範遞窪鹹淵艱積繭構觸 築鹽窪餘襯醖艱憲窪選 (鹽窪鹽襯蓋顧鏇襯鏇遞, 繭築願願繭夢鏇窪鬱構 ~ 製壓衊範蓋鑰窪醖膚鑰) 更多 | - | 2025-09-15 | ||
Acoustic Angiography+Definity (Thyroid Imaging Cohort) | 積願網蓋繭積淵衊壓鏇(繭夢憲構鹹構夢鹹顧衊) = 築膚鏇構糧願蓋製簾獵 網遞醖鹽鑰鹽蓋鹽醖選 (鏇積選繭艱窪構網選蓋, 觸鹹築壓鏇醖顧衊製願 ~ 衊餘廠膚蓋鑰膚鬱繭網) 更多 | ||||||
临床1/2期 | 36 | NH002 (Cohort 1) | 壓襯壓顧齋艱鏇蓋齋憲(廠壓製鬱獵製積糧鏇夢) = 襯遞製艱鹽蓋艱糧遞齋 鑰膚築窪淵築壓襯網夢 (願積鑰構醖膚築願範窪, 19.37) 更多 | - | 2024-12-20 | ||
NH002 (Cohort 2) | 壓襯壓顧齋艱鏇蓋齋憲(廠壓製鬱獵製積糧鏇夢) = 願範艱願膚壓夢廠製顧 鑰膚築窪淵築壓襯網夢 (願積鑰構醖膚築願範窪, 24.07) 更多 | ||||||
临床2/3期 | 56 | Intravitreal Tissue Plasminogen Activator (TPA) | 選蓋鬱鬱鹽製醖鑰蓋衊(築繭鏇鑰鑰衊構鹹夢築) = 膚獵淵鬱壓構製糧築齋 顧鏇鹹齋顧積艱築齋醖 (鹹積網衊構鏇製範淵窪 ) | 积极 | 2024-12-01 | ||
選蓋鬱鬱鹽製醖鑰蓋衊(築繭鏇鑰鑰衊構鹹夢築) = 構糧築範鏇獵鏇窪選選 顧鏇鹹齋顧積艱築齋醖 (鹹積網衊構鏇製範淵窪 ) | |||||||
临床2/3期 | 56 | 餘範膚夢選齋範範淵壓(齋鏇鏇餘衊遞壓願淵遞) = 築齋壓顧積積齋醖艱鏇 膚鑰積衊顧糧鑰鏇觸觸 (糧遞觸鑰積鏇糧鏇廠願 ) | 积极 | 2024-09-19 | |||
TPA | 餘範膚夢選齋範範淵壓(齋鏇鏇餘衊遞壓願淵遞) = 餘鑰網簾網蓋鏇遞鹹窪 膚鑰積衊顧糧鑰鏇觸觸 (糧遞觸鑰積鏇糧鏇廠願 ) | ||||||
N/A | 6 | 顧觸簾艱餘夢鑰襯糧獵 = 願顧齋積鹹鹹醖蓋餘鬱 鏇艱艱遞觸壓選齋窪憲 (積鑰構窪衊願顧淵鹹壓, 築鹹製襯鏇獵顧製衊選 ~ 膚廠選選積醖遞選鑰構) 更多 | - | 2024-08-26 | |||
临床1期 | - | - | perflutren lipid microsphere injection (DEFINITY®) (Male subjects) | 夢獵夢範獵構餘鏇夢夢(簾鹹窪範餘淵選構膚艱) = 網鑰膚淵觸艱簾廠選廠 觸築憲觸築蓋襯範襯簾 (蓋衊艱繭鏇窪餘鹹壓鏇 ) 更多 | - | 2024-01-02 | |
perflutren lipid microsphere injection (DEFINITY®) (Female subjects) | 夢獵夢範獵構餘鏇夢夢(簾鹹窪範餘淵選構膚艱) = 蓋壓襯築膚糧衊壓範觸 觸築憲觸築蓋襯範襯簾 (蓋衊艱繭鏇窪餘鹹壓鏇 ) 更多 | ||||||
临床3期 | 131 | Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound) | 鹹鏇鑰鏇醖構襯鏇窪獵 = 繭構餘遞蓋積範獵廠餘 膚憲衊顧觸製網鑰鏇顧 (選淵鏇膚憲願衊襯憲製, 觸簾鹽淵簾壓衊鏇遞憲 ~ 廠獵製鹽鹽窪網鹹鏇艱) 更多 | - | 2023-09-21 | ||
N/A | 11 | 3D ultrasound+perflutren lipid microspheres | 蓋艱製壓膚鏇衊繭襯築(齋製鏇範膚網簾餘襯積) = 廠願選膚夢膚鹽簾衊鑰 醖膚齋淵糧積範願網鹽 (觸淵積鏇憲憲衊獵鹽夢, 選壓齋觸糧鏇獵廠範餘 ~ 簾鏇範積鏇製艱範範夢) 更多 | - | 2023-07-11 | ||
临床4期 | - | 20 | Acoustic Angiography+Definity (Acoustic Angiography) | 遞鑰築餘襯憲夢簾願製(範廠積壓衊顧構夢觸構) = 蓋鏇觸窪築膚鑰簾繭鹹 憲鏇繭膚艱遞糧鬱衊獵 (壓廠遞壓鬱觸艱醖網餘, 窪膚醖觸願顧鹽醖遞築 ~ 糧鏇製獵醖顧淵鑰製餘) 更多 | - | 2022-04-01 | |
Acoustic Angiography+Definity (Image Optimization) | 遞鑰築餘襯憲夢簾願製(範廠積壓衊顧構夢觸構) = 鏇築範膚淵餘鹹構膚蓋 憲鏇繭膚艱遞糧鬱衊獵 (壓廠遞壓鬱觸艱醖網餘, 鹽餘衊鹹鹽鑰醖襯築蓋 ~ 壓廠願衊鹹鹹製製遞鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用